News from UvA
Angewandte Chemie profiles Jarl Ivar van der Vlugt.
The current issue of Angewandte Chemie, one of the top journals in the chemistry domain, contains a profile of Jarl Ivar van der Vlugt, assistant professor at the research group for Homogeneous, Supramolecular and Bio-Inspired Catalysis of the Van ‘t Hoff Institute for Molecular Sciences (HIMS).
Jarl Ivar van der Vlugt receives ECHO grant for novel amination concept
The Netherlands Organisation for Scientific Research (NWO) has awarded chemist dr.ir. Jarl Ivar van der Vlugt of the Van ‘t Hoff Institute for Molecular Sciences an ECHO project grant of 260,000 euros. Van der Vlugt will use the grant for the development of a novel method for the controlled, selective and efficient conversion of alkenes to amines.
Three winners in ACE Venture Lab bootcamp Sustainable Chemistry
The ACE Venture Lab bootcamp which was organised on the initiative of the University of Amsterdam’s Research Priority Area Sustainable Chemistry held a pleasant surprise. Not just one but three of the participants were awarded financial support and mentoring during the startup of their chemistry-based businesses.
Gert-Jan Gruter, professor by special appointment of Industrial Sustainable Chemistry
Dr G.J.M. Gruter (1963) has been named professor by special appointment of Industrial Sustainable Chemistry (ISC) at the Faculty of Science (FNWI) of the University of Amsterdam, effective from 20 October 2016. The chair was established on behalf of the Stichting Beta Plus and facilitated by Avantium.
Chemistry driven by the sun, for a sustainable future
A group of European chemists including Prof. Joost Reek of the University of Amsterdam’s research priority area Sustainable Chemistry has recently published a whitepaper on Solar-Driven Chemistry. They show that it is possible, and even necessary for a sustainable future, to drive chemical reactions using solar energy.
Peptide-based vaccination against VEGF results in efficient antitumor activity
A research team including professor Peter Timmerman of the University of Amsterdam’s Van ‘t Hoff Institute for Molecular Sciences (HIMS) has developed a peptide-based vaccine enabling a successful active anti-tumor immunization therapy targeting the growth hormone Vascular Endothelial Growth Factor (VEGF). Suppression of tumor growth has already been established in mice and exploratory studies in patients are now underway at VU Medical Center (Amsterdam). The encouraging preclinical results were published last week in PNAS (Proceedings of the National Academy of Sciences of the USA).
Ron Wever receives Vanadis award
Emeritus professor Ron Wever of the University of Amsterdam’s Van ‘t Hoff Institute for Molecular Sciences (HIMS) has been named the recipient of the 7th Vanadis Award for his research on vanadium haloperoxidases. Wever, former head of the Biocatalysis research group at HIMS, has spent a considerable part of his scientific career investigating these enzymes both in fundamental and application-oriented perspectives.